BEVERLY HILLS, CA , March 14, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, announced today the potential for using its drug RP-323 (TPA) in the treatment of Hodgkin's lymphoma.

Hodgkin’s lymphoma is a cancer that is found most frequently in two different age groups: 15 – 35 and over 55.  It occurs in both sexes although it is more common in males. Cancer cells invade and destroy the architecture of the lymph nodes and infiltrate the liver, the spleen or other parts of the body.  In the U.S., more than 100,000 people suffer from Hodgkin's lymphoma.

"A phase I clinical trial conducted at The Cancer Institute of New Jersey have shown that RP-323 treatment reduced a palpable tumor mass after three weeks in a patient with Hodgkin's lymphoma. We look forward to being able to commence clinical trials in the future to prove that using RP-323 alone or in combination with other anticancer agents will have significant therapeutic activity against Hodgkin's lymphoma,” said Rich Pharmaceuticals CEO, Ben Chang.  "Clinical studies in China have also demonstrated that IV administration of RP-323 resulted in remission in some patients with myelocytic leukemia."

About Rich Pharmaceuticals:

Rich Pharmaceuticals, Inc. is a clinical-stage Biopharmaceutical Company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Learn more at www.richpharmaceuticals.com.

Forward-Looking Statements:

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, including the business and product development plans contained in this news release, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.


Contact:                                                               

Paul Knopick
Pknopick@eandecommunications.com
940.262.3584